Neuroendocrine biomarkers of prolonged exposure treatment response in military-related PTSD
Introduction
Between 12 % and 20 % of military service members returning from Afghanistan and Iraq suffer from posttraumatic stress disorder (PTSD) (Hoge et al., 2004). Left untreated, PTSD can result in significant psychological, physical, and economic burden. While effective treatments for PTSD such as prolonged exposure (PE) have been developed (Rauch et al., 2012), only specially trained mental health providers can deliver these treatments, and accessing these providers can be difficult. In addition, a significant number of patients can remain symptomatic following treatment or are unable to utilize these treatments to their full potential (Rauch et al., 2012). Treatment optimization is essential to reducing PTSD’s substantial personal and social costs. A better understanding of the biological processes implicated in treatment change could help optimize therapy outcomes through increased efficiency and efficacy of response.
PE has the most scientific data supporting its use and has been shown effective in treating over 40 % of service members (Foa et al., 2018) and veterans (U.S. Department of Veterans Affairs and U.S. Department of Defense, 2017) to remission. However, optimizing PE to make it both more efficacious and efficient constitutes a formidable challenge. While PE has a theoretical foundation in emotional processing theory (Foa et al., 2019), detailed information about the neurobiological mechanisms involved in how PE works is lacking. Integrating affective neuroscience methodology, such as biomarker identification, with ongoing treatment studies to learn more about the mechanisms of change is needed.
Accumulating evidence suggests that key biological mechanisms of change in PTSD include neuroendocrine and neurosteroid systems. Methodological differences (e.g., different tasks, time of day, collection standards, etc.) and equivocal results are common in the research on hypothalamic pituitary adrenal (HPA) axis activity (Pan et al., 2018). Despite inconsistencies, the weight of the evidence supports that PTSD is related to abnormalities in HPA axis activity, specifically enhanced HPA axis negative feedback inhibition (Liberzon et al., 1999), attenuated cortisol awakening response (Neylan et al., 2005), and attenuated cortisol response to trauma memories (Pitman et al., 2012; Walsh et al., 2013). PTSD is also associated with dysregulation of allopregnanolone, pregnanolone (Cruz et al., 2019; Pineles et al., 2018; Rasmusson and Pineles, 2018; Schule et al., 2014), and dehydroepiandrosterone (DHEA/DHEAS) (Bicanic et al., 2013; Butterfield et al., 2005; Gill et al., 2008; Rasmusson et al., 2017; Sondergaard et al., 2002; Van Voorhees et al., 2013), endogenously produced neurosteroids with anxiolytic and antidepressant properties (Belelli and Lambert, 2005; Genud et al., 2009; Naert et al., 2007; Pibiri et al., 2008). Furthermore, blunted cortisol reactivity to an acute stressor before trauma exposure is associated with an increased risk for developing PTSD following trauma exposure (Galatzer-Levy et al., 2014), and decreased cortisol response in the acute aftermath of trauma exposure is associated with an increased risk for developing PTSD (Walsh et al., 2013).
Evidence suggests that PTSD treatment response may be associated with changes to neuroendocrine systems (Rauch et al., 2015; Sageman and Brown, 2006). Neuroendocrine factors may contribute to individual differences in response to PE treatment and serve as biomarkers of PTSD treatment response. The utility of assessing HPA axis markers as predictors of treatment response is highlighted by previous work showing that lower cortisol awakening response and increased cortisol reactivity to a brief personal trauma script prior to treatment both predict better response to PTSD treatment (Rauch et al., 2015). In addition, one study showed lower response of salivary cortisol following exposure therapy in rape survivors with PTSD (Gerardi et al., 2010). Another showed that lower pretreatment salivary cortisol in response to a trauma potentiated startle paradigm predicted treatment response in those patients who received alprazolam in combination with virtual reality exposure therapy (Norrholm et al., 2016). Finally, another study documented that a poor response to PE showed increased in-session cortisol response over the course of treatment (Rauch et al., 2017).
Concomitant with changes in HPA axis function in individuals with PTSD are alterations in endogenous neuroactive steroids that also have been implicated in the pathophysiology of PTSD. More specifically, allopregnanolone and pregnanolone (ALLO used when the two are presented combined) (Rasmusson et al., 2006; Schule et al., 2014) and dehydroepiandrosterone/dehydroepiandrosterone sulfate (DHEA[S]) (Gill et al., 2008; Sondergaard et al., 2002; Van Voorhees et al., 2013) are endogenous neuroactive steroids with both anxiolytic and antidepressant properties (Belelli and Lambert, 2005; Pibiri et al., 2008). ALLO is an anxiolytic agent that acts as positive allosteric of gamma-aminobutyric acid A (GABAA) receptors, and DHEA(S) has neuroprotective, antioxidant, antihypertensive, anti-inflammatory, and anti-glucocorticoid effects (Maninger et al., 2009) via its actions as a GABA(A) receptor noncompetitive antagonist and positive allosteric modulator at the N-methyl-d-aspartate (NMDA) receptor (for a review, see Maninger et al., 2009). In women and men with PTSD, allopregnanolone/pregnanolone concentrations in cerebrospinal fluid are reduced (Rasmusson et al., 2019, 2006) due to a block in allopregnanolone/pregnanolone synthesis (Pineles et al., 2018; Rasmusson et al., 2019). Importantly, a postmortem study of individuals with a diagnosis of PTSD found that the diagnosis is associated with gender-specific alterations in allopregnanolone, pregnanolone, and androsterone in the prefrontal cortex, with levels generally elevated in females and lowered in males (Cruz et al., 2019). DHEA is also dysregulated in PTSD, with data showing increased peripheral DHEA(S) concentrations (Gill et al., 2008; Sondergaard et al., 2002) and change in DHEA levels over the course of effective trauma-focused treatment (Olff et al., 2007). Sripada et al. (2014) have previously used functional magnetic resonance imaging (fMRI) to show that an acute pharmacological challenge of allopregnanolone and DHEA robustly enhanced activity in emotion regulation neurocircuits while dampening activity in emotion production regions of the brain (Sripada et al., 2014). Because higher allopregnanolone/pregnanolone has been associated with less anxiety in response to trauma-related stimuli (Rasmusson and Pineles, 2018) and DHEA elevations in response to ACTH challenge are consistently associated with resiliency in women with PTSD (Rasmusson et al., 2004), it is necessary to assess ALLO and DHEA(S) as prognostic indicators of PE treatment response alongside markers of HPA axis function.
The current report presents two separate studies designed to examine neuroendocrine biomarkers (cortisol, DHEA, DHEAS, allopregnanolone, pregnanolone) and their relationship to symptom severity (within assessment timepoint), change across PTSD treatment, and prediction of PTSD symptom change across treatment. The first is a randomized clinical trial of Web-based prolonged exposure and present-centered therapy. The second examines biological factors in a clinical effectiveness study of an intensive outpatient program based on PE.
Section snippets
Methods
The randomized controlled trial (RCT), titled “Web-PE: Internet-Delivered Prolonged Exposure Therapy for PTSD,” (PI: McLean) aimed to examine the efficacy of a Web version of PE, “Web-PE,” comparing it to an active, control therapy, present-centered therapy (PCT) delivered in person. The primary outcome of this study was change in PTSD severity from pre- to post-treatment. Our biomarkers hypotheses for this study were as follows: (1) lower baseline cortisol responsivity to awakening and higher
Methods
To further examine the change in biomarkers over the course of treatment, blood previously collected from individuals participating in a nonrandomized, intensive outpatient effectiveness program, the Emory Healthcare Veterans Program (EHVP) was analyzed. The EHVP is a 2-week, intensive outpatient intervention program to address PTSD and other invisible wounds of war. Details of the treatment program have been previously published (Yasinski et al., 2018), with the core program focused on
Discussion
The current studies replicate and extend findings of neuroendocrine factors related to PTSD severity and treatment response. Specifically, the RCT provides replication (Rauch et al., 2015) of two important correlates: CAR and cortisol response to script-driven imagery with PTSD severity. The EHVP study extends the understanding of these biological factors, identifying three preliminary biomarkers of treatment response: baseline allopregnanolone, pregnanolone, and cortisol response to a startle
Role of the funding source
The grant sponsor played no role in study design; the collection, analysis, and interpretation of data; the writing of this paper; or the decision to submit this paper for publication.
Disclaimer
The views expressed herein are solely those of the authors and do not reflect an endorsement by or the official policy or position of the U.S. Army, the Department of Defense, the Department of Veterans Affairs, or the U.S. Government.
Data statement
The data that support the findings of this research are available upon reasonable request from the first author.
Author note
Drs. Michopoulos, Post, Sherrill, & Yasinski and Ms. Black do not have any conflicts or disclosures.
Dr. Rauch receives support from Wounded Warrior Project (WWP), Department of Veterans Affairs (VA), National Institute of Health (NIH), Woodruff Foundation, and Department of Defense (DOD). Dr. Rauch receives royalties from Oxford University Press. Dr Kim has nothing to disclose. Dr. Powell has nothing to disclose. Dr. Tuerk has nothing to disclose. Dr. Simon has funding from the American
CRediT authorship contribution statement
Sheila A.M. Rauch: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing. Rebecca Sripada: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing - review & editing. Mark Burton: Conceptualization, Data curation, Formal analysis, Software,
Declaration of Competing Interest
Dr. Rauch receives support from Wounded Warrior Project (WWP), Department of Veterans Affairs (VA), National Institute of Health (NIH), Woodruff Foundation, and Department of Defense (DOD). Dr. Rauch receives royalties from Oxford University Press. Dr. Sripada is supported by U.S. Department of Veterans Affairs Health Services Research & Development Service.
Mark Burton has nothing to disclose.
Dr. Michopoulos receives support from the National Institute of Health (NIH).
Kimberly Kerley has
Acknowledgments
This work is supported by an award to Carmen P. McLean (W81XWH-14-1-0008) from the U.S. Department of Defense Psychological Health and Traumatic Brain Injury Research Program, which is part of the Defense Health Program and Defense Medical Research and Development Program, and by an award to Sheila A.M. Rauch through Consortium to Alleviate PTSD (CAP) award numbers W81XWH-13-2-0065 from the U.S. Department of Defense, Defense Health Program, Psychological Health and Traumatic Brain Injury
References (53)
- et al.
The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women
Pharmacol. Biochem. Behav.
(2006) - et al.
Salivary cortisol and dehydroepiandrosterone sulfate in adolescent rape victims with post traumatic stress disorder
Psychoneuroendocrinology
(2013) - et al.
Cortisol response to an experimental stress paradigm prospectively predicts long-term distress and resilience trajectories in response to active police service
J. Psychiatr. Res.
(2014) - et al.
Neuroendocrine and psychophysiologic responses in PTSD: a symptom provocation study
Neuropsychopharmacology
(1999) - et al.
Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS)
Front. Neuroendocrinol.
(2009) - et al.
When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates
J. Anxiety Disord.
(2019) - et al.
The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer’s disease
Biol. Psychiatry
(2006) - et al.
Design of a randomized controlled trial examining the efficacy and biological mechanisms of web-prolonged exposure and present-centered therapy for PTSD among active-duty military personnel and veterans
Contemp. Clin. Trials
(2018) - et al.
Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats
Psychoneuroendocrinology
(2007) - et al.
PTSD symptoms predict waking salivary cortisol levels in police officers
Psychoneuroendocrinology
(2005)
Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy
Behav. Res. Ther.
Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD
Psychoneuroendocrinology
PTSD in women is associated with a block in conversion of progesterone to the GABAergic neurosteroids allopregnanolone and pregnanolone measured in plasma
Psychoneuroendocrinology
Free and Easy Wanderer plus (FEWP) improves behavioral deficits in an animal model of post-traumatic stress disorder by stimulating allopregnanolone biosynthesis
Neurosci. Lett.
Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder
Biol. Psychiatry
Neuroactive steroids and PTSD treatment
Neurosci. Lett.
Relationships between cerebrospinal fluid GABAergic neurosteroid levels and symptom severity in men with PTSD
Psychoneuroendocrinology
The role of allopregnanolone in depression and anxiety
Prog. Neurobiol.
Assessment of the cortisol awakening response: expert consensus guidelines
Psychoneuroendocrinology
Cortisol at the emergency room rape visit as a predictor of PTSD and depression symptoms over time
Psychoneuroendocrinology
Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: randomized trial showing improved treatment retention and outcome
Psychoneuroendocrinology
Neurosteroids: endogenous regulators of the GABA(A) receptor
Nat. Rev. Neurosci.
Neuroactive steroids and suicidality in posttraumatic stress disorder
Am. J. Psychiatry
Neurosteroid levels in the orbital frontal cortex of subjects with PTSD and controls: a preliminary report
Chronic Stress
Effect of prolonged exposure therapy delivered over 2 weeks vs 8 weeks vs present-centered therapy on PTSD symptom severity in military personnel: a randomized clinical trial
JAMA
Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences
Cited by (3)
Changes in indicators of stress-regulating systems in adolescents of Ukraine during the period of military actions
2023, Modern Pediatrics. Ukraine